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The utility of high-flow nasal cannula 
oxygen therapy in the management 
of respiratory failure secondary to 
COVID-19 pneumonia
To the Editor: COVID-19 is a potentially fatal infection caused 
by SARS-CoV-2.[1] As of 4 May 2020, more than 6 000 cases 
had been confirmed in South Africa (SA) with numbers rising 
steadily, a situation that will place a major strain on the country’s 
health resources, including its ability to provide intensive care and 
ventilatory support to patients with severe disease.[2]
Recent evidence suggests that intubation and mechanical 
ventilation may have limited impact on outcome, with mortality as 
high as 88% in one large cohort of patients in New York.[3] It has been 
suggested that non-invasive ventilation may be more appropriate, 
particularly for the so-called ‘L phenotype’, which is characterised 
by low elastance (i.e. high compliance).[4] High-flow nasal cannula 
(HFNC) oxygen therapy comprises an air/oxygen blender, an active 
humidifier, a single heated circuit, and a nasal cannula. It delivers 
adequately heated and humidified medical gas at up to 60 L/min 
of flow and is considered to have a number of physiological effects, 
including positive end-expiratory pressure (PEEP), reduction of 
anatomical dead space, a constant fraction of inspired oxygen, and 
adequate humidification.[5]
Following international reports of improved survival rates with 
non-invasive ventilation, the COVID-19 intensive care unit (ICU) 
at Tygerberg Hospital, Cape Town, changed its standard operating 
procedure in mid-April 2020 from the initially promoted ‘early 
intubation and mechanical ventilation’ to ‘HFNC oxygen therapy’, to 
avoid intubation.
The first 6 admissions to our ICU were intubated and mechanically 
ventilated, with the next 7 treated with initial HFNC oxygen therapy. 
The demographic data, comorbidities and severity indices were 
comparable. No patient was enrolled into a therapeutic trial. All 
patients (6/6) who were intubated and ventilated died, compared with 
1/7 (14.2%) managed with HFNC oxygen therapy, suggesting that 
HFNC oxygen therapy may be associated with a lower mortality rate.
Our observations echo recent evidence.[1,3] Gattinoni et al.[4] have 
postulated that a significant proportion of patients with COVID-
19 pneumonia have features not seen in acute respiratory distress 
syndrome (ARDS), including severe hypoxaemia with near-normal 
respiratory system compliance. The hypoxaemia is still poorly 
understood, and may be due to abnormalities of perfusion, or loss 
of hypoxic vasoconstriction leading to a low ventilation-to-perfusion 
ratio. Studies have reported that only ground-glass densities 
are present on computed tomography scans, primarily located 
subpleurally and along the lung fissures. Consequently, lung weight 
is only moderately increased and the recruitability remains low, as 
the amount of non-aerated tissue is negligible.[4] ‘Traditional’ invasive 
ventilation with high PEEP may therefore in fact lead to ventilator-
induced lung injury and a worse prognosis.
It should be emphasised that a proportion of COVID-19 patients 
will present with a more ‘classic’ ARDS picture, and HFNC oxygen 
therapy will probably not be of benefit in these cases.[4] Moreover, 
HFNC oxygen therapy requires very high-flow oxygen, far higher 
than mechanical ventilators utilise, and the infrastructure of many 
hospitals may preclude the widespread use of this technology.[5] 
Many clinicians initially shied away from HFNC, citing potential 
aerosolisation of respiratory secretions with concomitant infection 
control risk. New evidence suggests that HFNC oxygen is in fact 
associated with a low risk of airborne transmission.[6,7] To minimise 
transmission risk, care in a negative-pressure ventilated room is 
preferred. Alternatively, the patient may be nursed in a single room, 
or confirmed COVID-19 patients may be cohorted together. Use of 
appropriate personal protective equipment must be adhered to.
While HFNC oxygen therapy is by no means a panacea for severe 
pneumonia secondary to the SARS-CoV-2 virus, it may offer a less 
harmful method of ventilatory support, particularly early in the 
disease, and its wider utilisation should be considered in SA.
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